Vascular Biogenics Ltd. (VBLT) Issues Earnings Results, Beats Estimates By $0.03 EPS
Vascular Biogenics Ltd. (NASDAQ:VBLT) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03.
Shares of Vascular Biogenics (NASDAQ:VBLT) opened at 4.80 on Friday. The company has a 50 day moving average price of $5.06 and a 200-day moving average price of $4.29. The stock’s market capitalization is $113.29 million. Vascular Biogenics has a 1-year low of $2.76 and a 1-year high of $7.58.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Menta Capital LLC boosted its position in Vascular Biogenics by 4.1% in the second quarter. Menta Capital LLC now owns 33,200 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 1,300 shares during the period. KCG Holdings Inc. acquired a new position in Vascular Biogenics during the third quarter valued at approximately $302,000. Turner Investments L.P. acquired a new position in Vascular Biogenics during the second quarter valued at approximately $1,007,000. Macquarie Group Ltd. acquired a new position in Vascular Biogenics during the second quarter valued at approximately $1,521,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in Vascular Biogenics during the second quarter valued at approximately $1,844,000. Institutional investors and hedge funds own 14.42% of the company’s stock.
Several research analysts have weighed in on the company. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 26th. Roth Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Vascular Biogenics in a research note on Tuesday, August 16th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $10.90.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.